ACSL4 Antibody

Code CSB-PA289963
Size US$299
  • The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using CSB-PA289963(ACSL4 Antibody) at dilution 1/25, on the right is treated with fusion protein. (Original magnification: ×200)
  • Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-4: Hepg2 cells, hela cells, 293T cells, human fetal kidney tissue, Primary antibody: CSB-PA289963(ACSL4 Antibody) at dilution 1/225, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 15 seconds
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No. O60488
Target Names ACSL4
Alternative Names ACSL4; ACS4; FACL4; LACS4; Long-chain-fatty-acid--CoA ligase 4; Arachidonate--CoA ligase; Long-chain acyl-CoA synthetase 4; LACS 4
Raised in Rabbit
Species Reactivity Human,Mouse,Rat
Immunogen Fusion protein of Human ACSL4
Immunogen Species Homo sapiens (Human)
Conjugate Non-conjugated
Isotype IgG
Purification Method Antigen affinity purification
Concentration It differs from different batches. Please contact us to confirm it.
Buffer -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
Form Liquid
Tested Applications ELISA,WB,IHC
Recommended Dilution
Application Recommended Dilution
ELISA 1:2000-1:5000
WB 1:500-1:2000
IHC 1:25-1:100
Protocols ELISA Protocol
Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Catalyzes the conversion of long-chain fatty acids to their active form acyl-CoA for both synthesis of cellular lipids, and degradation via beta-oxidation. Preferentially activates arachidonate and eicosapentaenoate as substrates. Preferentially activates 8,9-EET > 14,15-EET > 5,6-EET > 11,12-EET. Modulates glucose-stimulated insulin secretion by regulating the levels of unesterified EETs. Modulates prostaglandin E2 secretion.
Gene References into Functions
  1. The regulatory network among peroxisomal ABCD2:ACSL4:VLCFA serves as a novel regulator of cartilage homeostasis, and these data may provide novel insights into the role of peroxisomal fatty acid metabolism in pathogenesis of human osteoarthritis (OA). PMID: 30264402
  2. Study demonstrated that ACSL4 was overexpressed in HCC. PMID: 28887439
  3. studies have identified a novel substrate-induced posttranslational regulatory mechanism by which AA downregulates ACSL4 protein expression in hepatic cells. PMID: 24879802
  4. Data show that ELOVL7, SOCS3, ACSL4 and CLU were upregulated while PRKAR1A and ABCG1 were downregulated in the phlegm-dampness group. PMID: 27928700
  5. ACSL4 is not only a sensitive monitor of ferroptosis, but also an important contributor of ferroptosis. PMID: 27565726
  6. Silencing of ACSL4 eliminated the 17beta-estradiol-induced increase in AA and EPA uptake. PMID: 28334272
  7. ACSL4 plays a tumor-suppressive role in gastric cancer. PMID: 26949059
  8. Suggest role for ACSL4 expression in development of castration-resistant prostate cancer. PMID: 26636648
  9. we demonstrate that ACSL4 can be considered a novel activator of the mTOR pathway PMID: 26536660
  10. In vitro analysis showed that a recombinant COX-2 enzyme more effectively metabolized 5(S)-HETE to 5-11-diHETE compared to COX-1 enzyme. PMID: 26282205
  11. Upregulation of ACSL4 is responsible for the increase in triacylglycerol species containing long polyunsaturated fatty acids during activation of hepatic stellate cells. PMID: 25500141
  12. Report PPARdelta-mediated regulatory mechanism for ACSL4 expression in liver tissue and cultured hepatic cells. PMID: 25645621
  13. ACSL4 can serve as both a biomarker for, and mediator of, an aggressive breast cancer phenotype. PMID: 24155918
  14. This study found no significant relationship between FACL4 and cognitive function. PMID: 20452052
  15. conclude that in our model system exogenous fatty acids are channeled preferentially towards phosphatidylinositol by ACSL4 overexpression PMID: 24201376
  16. MiR-205 down-regulates ACSL4 through targeting its 3'UTR in hepatoma cells. PMID: 24576478
  17. The functional interaction between Acyl-CoA synthetase 4, 5-lipooxygenase and cyclooxygenase-2 controls tumor growth. PMID: 22808264
  18. the involvement of SHP2 activity in the regulation of the expression of the fatty acid-metabolizing enzyme ACSL4 PMID: 21903867
  19. A total of six novel and 11 known single nucleotide polymorphisms were identified. Further studies are warranted to analyze the candidate genes at Xq11.1-q21.33. PMID: 21384559
  20. CSL4 modulates PGE release from human erial smooth muscle cells. PMID: 21242590
  21. Data suggest that the development of combinatory therapies that profit from the ACSL4, lipooxygenase and COX-2 synergistic action may allow for lower medication doses and avoidance of side effects. PMID: 21085606
  22. Fatty acid CoA ligase 4 is up-regulated in colon adenocarcinoma. PMID: 11731423
  23. FACL4, encoding fatty acid-CoA ligase 4, is mutated in nonspecific X-linked mental retardation PMID: 11889465
  24. FACL4 is highly expressed in hippocampal and cerebellar neurons and may have a role in X linked mental retardation. PMID: 12525535
  25. Overexpression of Fatty acid-CoA ligase 4 is associated with human hepatocellular carcinoma PMID: 12824887
  26. FACL4 is involved in the hepatocellular carcinoma tumorigenesis and both cAMP and p38 MAPK pathways are associated with the regulation of FACL4 PMID: 15849811
  27. Disruption of DMD and the absence of ACSL4 in a patient are responsible for neuromuscular disease and cognitive impairment. PMID: 16276108
  28. FACL4 affects HCC cell growth and suggest that modulation of FACL4 expression/activity is an approach for treatment of HCC. PMID: 17934335
  29. FACL4 might play a role in the growth of hepatic cancer cells. PMID: 18059177
  30. No association between polymorphisms in the FACL4 (fatty acid-CoA ligase 4) gene and nonspecific mental retardation in Qin-Ba mountain region of China. PMID: 18614287
  31. The common SNP (C to T substitution) in the first intron of the FACL4 gene is associated with altered Fatty Acid composition of plasma phosphatidylcholines in patients with metabolic syndrome . PMID: 19346733
  32. ACSL4 can substitute the functions of dAcsl(l(2)44DEa in organismal viability, lipid storage and the neural wiring in visual center. PMID: 19617635

Show More

Hide All

Involvement in disease Mental retardation, X-linked 63 (MRX63); Alport syndrome with mental retardation, midface hypoplasia and elliptocytosis (ATS-MR)
Subcellular Location Mitochondrion outer membrane; Single-pass type III membrane protein. Peroxisome membrane; Single-pass type III membrane protein. Microsome membrane; Single-pass type III membrane protein. Endoplasmic reticulum membrane; Single-pass type III membrane protein. Cell membrane.
Protein Families ATP-dependent AMP-binding enzyme family
Database Links

HGNC: 3571

OMIM: 300157

KEGG: hsa:2182

STRING: 9606.ENSP00000339787

UniGene: Hs.268785

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
7505 Fannin St. Ste 610-312, Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

© 2007-2022 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1